US EditionPublished • loading... • Updated
REPATHA® CUTS RISK OF FIRST MAJOR CARDIOVASCULAR EVENTS BY 31% IN HIGH-RISK PATIENTS WITHOUT KNOWN SIGNIFICANT ATHEROSCLEROSIS
VESALIUS-CV trial showed Repatha cut first major cardiovascular events by 31% in 3,655 high-risk diabetes patients without significant atherosclerosis over 4.8 years.
Summary by WBOC 16
6 Articles
6 Articles
PCSK9 Drug Prevents First Heart Events in Diabetes Patients Without Atherosclerosis
(MedPage Today) -- NEW ORLEANS -- Evolocumab (Repatha) reduced risk of a first major cardiovascular (CV) event in patients with diabetes but no known atherosclerosis in a substudy of the VESALIUS-CV trial. The PCSK9 inhibitor cut relative risk...
·New York, United States
Read Full Article
Coverage Details
Total News Sources6
Leaning Left0Leaning Right0Center3Last UpdatedBias Distribution100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium
